Peptides›Metabolic›Dulaglutide

Dulaglutide

/ GLP-1 analog fused to IgG4 Fc fragment; long-acting GLP-1 receptor agonist

TIER 1 · ClinicalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · Trulicity

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · GLP-1 analog fused to IgG4 Fc fragment; long-acting GLP-1 receptor agonistCATEGORY · Metabolic

FDA-approved for type 2 diabetes (2014). Eli Lilly's once-weekly GLP-1 predecessor to tirzepatide.

§ B · Mechanism of action

Dulaglutide is a GLP-1 analog fused to an IgG4 Fc fragment. The Fc fusion confers neonatal Fc receptor (FcRn) recycling and a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. AWARD clinical program established efficacy in type 2 diabetes.

§ C · Human clinical evidence

Extensive. AWARD program supported FDA approval. REWIND cardiovascular outcomes trial (Gerstein 2019, Lancet) demonstrated MACE reduction in T2DM with and without established CV disease.

§ F · Safety signal

Class GLP-1 adverse event profile. Same thyroid C-cell boxed warning, pancreatitis, gallbladder disease, and AKI warnings. Discontinuation rates for GI events modestly lower than early-generation GLP-1 agonists.

§ H · Regulatory status

Regulatory status

FDA status:: FDA-approved
Compounding:: Not eligible for compounding (approved, not in shortage)